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The effect of oral administration of Hochuekkito (HET; Bu-Zhong-Yi-Qi-Tang in Chinese),
a traditional Japanese herbal medicine, on mucosal IgA immune response was investigated.
To induce the antigen-specific antibodies in mucosal site, ovalbumin (OVA)-entrapped
biodegradable microparticles (OVA-microparticles) were used as an antigen. Mice were orally
immunized with OVA-microparticles for 3 successive days with intragastric gavage. From 7
days after the onset of immunization, the mice were boosted twice a week with the same antigen
for 2 weeks. HET or water alone was orally administered to the mice via the intragastric route
from 7 days before to 27 days after the onset of immunization. Although no significant change
in total secretory IgA antibody level was observed in intestinal and nasal washes, OVA-specific
IgA titers in intestinal washes were significantly enhanced by oral administration of HET.
When lymphocytes from spleen, peripheral blood and Payer’s patches were investigated for
cytokines production, it was found that the IFN-g secretion from the lymphocytes was
increased by the administration of HET. Microarray analysis of Peyer’s patch cells revealed
enhanced expression of L-selectin gene. The increase of L-selectin positive cells in B
lymphocytes fraction was observed in Peyer’s patch cells and peripheral blood mononuclear
cells by flow cytometry. These results suggest that the enhanced IFN-g secretion and increased
population of L-selectin positive B lymphocytes by orally administered HET may partly
contribute to enhancement of IgA immune response against intestinal antigens, and orally
administered HET may strengthen defensive systems against various pathogens and food
antigens in intestine.
Keywords: DNA microarray–Hochuekkito–Kampo–L-selectin–mucosal IgA–Peyer’s
patch–OVA-microparticle
Introduction
Hochuekkito (HET; Bu-Zhong-Yi-Qi-Tang in Chinese) is
one of Kampo (Japanese herbal) medicines, which
consists of 10 component herbs, and well-known
Kampo formulas used as tonic. This formula has been
identified as an effective drug to improve function of the
digestive system and to strengthen defensive system
against various infections. It promotes certain biological
activities including enhancement of natural killer cells
(1) and macrophage activity (2). HET also has an
inhibitory effect on influenza virus infection via enhance-
ment of host immune responses in virus-infected mice (3).
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properly cited.Recently, we have found that orally administered HET
enhanced immune response against the intranasally
administered antigen (4).
The gut-associated lymphoreticular tissues exist on
intestinal mucosal sites and play an important role in
host defense including IgA response in the mucosal
immune system (5). The central aspect of a mucosal
immune response is the generation of antigen-specific
IgA antibodies at the external secretions. Once produced
by mature plasma cells, IgA is transported onto the
mucosal surface, where it interacts with invading patho-
gens by inhibiting their adherence and forming immune
complexes (6).
The inner surface of the intestinal tract possesses a
large area of mucosal membranes, and the intestinal
epithelial cells (IEC) sit at the interface between a lumen
and a lymphocyte-rich lamina propria. The cross talk
that occurs between these compartments serves to
maintain intestinal homeostasis. Because Kampo medi-
cines are taken orally, the gastric mucosal immune system
may act as one of the major targets for expression of
pharmacological activity. However, the modulating activ-
ity of Kampo medicines on mucosal immune system is
not fully understood.
In this research, we attempt to evaluate whether HET
can stimulate IgA antibody response against intestinal
antigen by using ovalbumin (OVA)-entrapped biodegrad-
able microparticles (OVA-microparticles), and found that
HET enhanced antigen-specific mucosal IgA response.
The present article deals with the effect of orally
administered HET on the enhanced mucosal IgA
response against intestinal antigen.
Materials and Methods
Materials
Spray-dried extract preparation of HET (TJ-41, Lot No.
920041001PO) was kindly supplied by Tsumura & Co.
(Tokyo, Japan). HET for 1day dose was prepared as
follows: a mixture of Astragali Radix (4g, roots of
Astragalus membranaceus Bunge), Atractylodis lanceae
Rhizoma (4g, rhizomes of Atractylodes lancea DC.),
Ginseng Radix (4g, roots of Panax ginseng C.A. Meyer),
Angelicae Radix (3g, roots of Angelica acutiloba
Kitagawa), Bupleuri Radix (2g, roots of Bupleurum
falcatum L.), Zizyphi Fructus (2g, fruits of Zizyphus
jujuba Miller var. inermis Rehder), Aurantii Bobilis
Pericarpium (2g, pericarps of ripe fruits of Citrus unshu
Markovich), Glycyrrhizae Radix (1.5g, roots of
Glycyrrhiza uralensis Fisch et DC.), Cimicifugae
Rhizoma (1g, rhizomes of Cimicifuga simplex
Wormskjord) and Zingiberis Rhizoma (0.5g, rhizomes
of Zingiber officinale Roscoe) was added to water and
extracted at 100C for 1h. The extracted solution was
filtered and spray-dried to obtain dry extract powder
(5g). Ministry of Health, Labour and Welfare in Japan
chose 5g of the extract as a dosage for 1day for adult
human. Chemical profile of HET obtained by the 3D
HPLC analysis is shown in Fig. 1.
Mice
Specific pathogen free C3H/HeJ female mice (6- to
8-weeks old) were obtained from SLC (Shizuoka,
Japan). Mice were maintained in a 24h light and dark
cycle (12h of light, 12h of darkness) and controlled
temperature (231C) and they had free access to
standard laboratory chow (Oriental Yeast Co., Tokyo,
Japan) and water. The procedure from the Prime
Minister’s Office of Japan (No. 6 of March 27, 1980)
for the care and use of laboratory animals was followed.
The experiments were conducted in accordance with
Guidelines for Animal Use and Experimentation of the
Kitasato Institute (Tokyo, Japan), and the approval
number of the animal experimentation was 2006-1-35-1
(Kitasato Institute). For oral administration to mice,
HET extract was suspended in distilled water at a
concentration of 100mgml
1. HET was orally
administered through a gastric tube once a day
(4:00 PM) in a volume of 100ml per 10g of body
weight, while control group was administered equal
volumes of water alone. During the experiments,
behavioral changes and/or motor deficit were not
observed in between the control and HET administered
groups, and decrease in body weight was also not
observed (data not shown).
Preparation of OVA-Microparticles
The OVA-microparticles were prepared using the water-in-
oil-in-water emulsion solvent evaporation technique
according to the methods of Jeffery et al. (7). OVA
(albumin, chicken egg white, grade V, Sigma, St Louis,
MO, USA) was dissolved in water to a concentration of
10%. Poly(DL-lactide-co-glycolide, 50:50) (PLG; Sigma)
was dissolved in dichloromethane to a concentration of
12%. Polyvinyl alcohol (PVA, Sigma) was dissolved in
water to a concentration of 2%. One milliliter of aqueous
OVA solution was emulsified with 10ml of PLG solution
using an ultrasonic homogenizer (Type 200, Branson,
Danbury, CT, USA). The resulting w/o emulsion was
then emulsified at high speed with 100ml of aqueous PVA
solution to produce a w/o/w emulsion. The w/o/w emulsion
was then stirred magnetically for 18h at room temperature
and pressure, to allow solvent evaporation and micro-
particle formation. The microparticles were isolated by
centrifugation, washed three times with water and freeze-
dried. The surface of OVA-microparticles as observed
under scanning electron microscope was free from
any pores or cracks (Fig. 2). Protein content of
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acid (8), and was 10.8% as OVA. OVA free blank micro-
particles were prepared identically in the absence of OVA.
Schedule for Immunization of OVA and HET
Administration
OVA-microparticles were suspended in 0.5ml of water,
and mice were immunized orally on days 0, 1, 2, 7, 10, 14
and 17 with 2mg of OVA antigen via the intragastric
route. HET were orally administered to the mice with
intragastric gavage from 7 days before to 27 days after
the starting of immunization.
Preparation of Nasal and Intestinal Washes
The small intestine was dissected and placed on an ice-
cold glass plate, and the lumen was flushed with 3ml of
cold phosphate-buffered saline (PBS) containing 0.1%
bovine serum albumin (BSA), 0.05% Tween 20 and a
protease inhibitor mixture (2.5mgml
1 aprotinin,
2.5mgml
1 pepstatin and 2.5mgml
1 leupeptin) to collect
the intestinal wash. The head of the mouse was removed
and the lower jaw was excised, a hypodermic needle was
Figure 1. Chemical profile of HET analyzed by 3D HPLC. The each peak of HET in the HPLC profile was identified by comparison of the retention
times and UV spectra of chemically defined standard compounds. HPLC condition was as follows: Column; Tosoh TSK GEL ODS-80Ts
(4.6250mm). Carrier A: 0.05M ammonium acetate (pH 3.6). Carrier B: Acetonitrile. Gradient: 10–100% carrier B linear in 60min. Flow rate:
1.0ml min
1. Injection volume: 30ml. Detector: Shimadzu SPD-M10A VP.
Figure 2. Scanning electron micrograph of OVA-microparticles. The
dried preparation was covered with a 10nm thick gold film by sputter
coating (JEOL, JFC-1200 FINE COATER, Tokyo, Japan), then
examined with a JSM-5600 scanning electron microscope (JEOL)
operated at an acceleration voltage of 5kV.
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and 500ml of the flushing solution described earlier was
injected to collect the nasal wash. The washes were
centrifuged 10min at 2330g and the supernatants were
immediately frozen and stored at 20C.
Detection of Anti-OVA IgA Antibody and Total
IgA by ELISA
The specific anti-OVA IgA antibody content of
the intestinal and nasal washes was determined by
enzyme-linked immunosorbent assay (ELISA). The
ELISA was performed as follows: microtiter plates
(Immulon 4 HBX, Thermo Labsystems; Franklin,
MA, USA) were coated overnight with 100ml per well
of 1% OVA. Unbound OVA on the plate was removed
by washing with PBS containing 0.05% Tween 20 (PBST,
300ml) four times. The plate was further incubated with
1% BSA in PBS (PBS–BSA) (300ml per well) at 37C for
1h, and washed with PBST four times. Serial dilution of
the intestinal and nasal washes was done with PBS–BSA.
The resulting dilutions were added to the wells (100ml per
well), and incubated at 37C for 1h. After the plate was
washed with PBST five times, biotin-labeled anti-mouse
IgA (clone R5-140) (PharMingen, San Diego, CA, USA),
which was diluted with PBST, was added to the wells and
incubated at 37C for 1h. Then the plate was washed six
times with PBST. Streptavidin-alkaline phosphatase
(Life Technologies, Gaithersburg, MD, USA) diluted
with PBST (1:2000) was added to each well and the
plates were then incubated at room temperature for
30min. The plate was washed with PBST five times, and
each well was incubated with 150ml of chromogenic
substrate solution (1mg of p-nitrophenylphosphate
disodium salt in 1ml of 10% diethanolamine buffer,
pH 9.8) at room temperature. The absorbance at 405nm
was measured during incubation using a microplate
reader (Model 450, Bio-Rad). Total IgA was measured
by a standard sandwich ELISA using anti-mouse IgA
(clone C10-3) and biotin-labeled anti-mouse IgA (R5-140)
(PharMingen, San Diego, CA, USA).
Detection of Cytokines by ELISA
The interferon (IFN)-g and interleukin (IL)-4 were
measured by using sandwich ELISA kit (Amersham
Biosciences AB, Uppsala, Sweden). The tests were per-
formed according to the supplier’s instruction manuals.
Preparation of Cell Suspension
Under light ether anesthesia, blood was obtained
aseptically by cardiac puncture, and spleen and Peyer’s
patches were removed. Peripheral blood mononuclear
cells (PBMC) were prepared from heparinized whole
blood using a standard Percoll density gradient. In brief,
the blood was layered onto the top of the discontinuous
gradient containing 67.5 and 40% of Percoll (Amersham
Biosciences AB). After centrifugation (600g for 20min),
the interface layer between 67.5 and 40% was carefully
removed and washed twice with Hanks’ balanced salt
solution (HBSS), and then resuspended in RPMI 1640




Peyer’s patch cells were isolated as previously described
(9). The cell viability was uniformly >95% as determined
by trypan blue exclusion, and always >95% of the cells
showed lymphocyte and <1% macrophage morphology
with characteristic staining.
Cell Culture and Cytokine Production Measurements
The lymphocytes were suspended at a density of 2.510
6
cells ml
1 in RPMI 1640–5% FBS. Five hundred microliter
of aliquots of cell suspension were dispensed into 48-well
flat bottom microculture plates (Falcon 3048, Becton
Dickinson, Franklin Lakes, NJ, USA) and cultured for
48h at 37C in a humidified atmosphere of 5% CO2-95%
air with 1mgml
1 of anti-mouse CD3 (145-2C11) for the
induction of cytokines. After the culture of lymphocytes,
the culture supernatants were collected and stored at
20C for the quantitative analysis of cytokines.
Isolation of Total RNA and Generation
of Biotin-labeled cRNA
Total RNA was purified using an RNeasy Mini kit
(Qiagen, Valencia, CA, USA). Residual genomic DNA in
the total RNA samples was removed by incubation with
10 units DNase I per 100mg total RNA (Ambion, Austin,
TX, USA) at 37C for 30min. RNA integrity was verified
using the Bioanalyzer 1000 (Agilent Technologies, Palo
Alto, CA, USA). Biotin-labeled cRNA was generated in
a two-step procedure. Initially, first-strand cDNAs were
synthesized from 4.0mg of total RNA using 1.0 unit of
SuperScript II RT (Invitrogen, Carlsbad, CA, USA) in
the presence of 100p mole T7 promoter Oligo dT primer.
After second-strand synthesis, the DNA was purified
with a DNA Clean and Concentrator-5 kit (Zymo
Research, Orange, CA, USA). The purified double-
stranded cDNA was transcribed into cRNA using the
MEGAscript in vitro transcription kit (Ambion). The
in vitro transcription reaction was carried out in a total
volume of 23.0ml consisting of 3.0ml of double-stranded
cDNA, 2.3mlo f1 0 Ambion reaction buffer, 2.3mlo f
10Ambion T7 enzyme mix and 15.4ml of NTP labeling
mix (7.5mM ATP, 7.5mM GTP, 5.625mM UTP,
5.625mM CTP, 1.875mM biotin-16-UTP and 1.875mM
biotin-11-CTP). The in vitro transcription reaction was
incubated at 37C for 16h in a thermocycler. The cRNA
was purified with an RNeasy Mini kit (Qiagen).
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A total of 500 unique murine sequences were used to
construct high-density oligonucleotide DNA microarrays.
Oligonucleotides were synthesized in situ using photo
deprotection chemistry with the Maskless Array Synthe-
sizer system (NimbleGen, Madison, WI, USA). The
microarrays were pre-hybridized with 1MES hybridiza-
tion buffer (100mM 2-morpholinoethanesulfonic acid,
1.0M Na
+, 20mM EDTA, 0.01% Tween 20), 40mgo f
herring sperm DNA and 200mg of acetylated BSA at
45C for 15min followed by hybridization with 10mgo f
denatured and fragmented cRNA per microarray at 45C
for 20h with constant rotation. After hybridization, the
microarrays were immediately washed extensively with
non-stringent buffer (6 SSPE, 0.01% Tween 20) at
room temperature followed by a stringent wash (100mM
MES salt and free acid solution, 0.1M Na
+, 0.01%
Tween 20) at 45C. After the final rinse with the non-
stringent buffer, the microarrays were stained with
1stain buffer (100mM MES, 1M Na
+, 0.05% Tween
20, 50mg ml
1 BSA and 1mg ml
1 Cy3-streptavidin) at
room temperature for 25min. The stain buffer was
removed, and the microarrays were rinsed once more
with non-stringent buffer. The microarrays were imme-
diately dried under a stream of argon gas and scanned
using an Axon GenePix 4000B scanner (Molecular
Devices, Union City, CA, USA) at 5mm resolution. The
data were extracted from the raw images using Nim-
bleScan software (NimbleGen, Madison, WI, USA), and
then processed using NANDEMO Analysis software
(GeneFrontier, Tokyo, Japan). Genes were regarded as
changed if the expression differed over 1.5-fold between
the two groups.
Flow Cytometry
The surface phenotypes of cells were identified by using
monoclonal antibodies. FITC-labeled anti-CD3 (clone
145-2C11), PE-labeled anti-CD45R/B220 (RA3-6B2) and
PE-labeled anti-CD62L (MEL-14) were purchased from
PharMingen (San Diego, CA, USA). Fluorescence stain-
ing was performed at 4C in 200ml HBSS–FBS, after
treatment of cells with unlabeled anti-CD16/32 Ab
(2.4G2) in the same amount of staining buffer. Stained
cells were then fixed with 1% paraformaldehyde dis-
solved in PBS and analyzed by flow cytometry (FCM) on
EPICS ELITE with logarithmic amplifier (Coulter Corp.,
Hialeah, FL, USA). Lymphoid cells were gated by the
forward and side scatter gating method for the analysis of
the lymphocyte population.
Statistical Analysis
Data were expressed as meanSD and differences
between groups were analyzed by analysis of variance
(ANOVA) followed by post hoc analysis using Scheffe’s
test using a personal computer with the StatView-J
program for Macintosh (SAS Institute Inc., Cary, NC,
USA), and Welch’s and Student’s t-test were performed
with DA Stats (ver 1.0, freeware soft, copyright 1993 by
Dr O. Nagata) after the variances of data were examined
using the F-test. The P-values <0.05 were considered
significant.
Results
Stimulation of Intestinal IgA Immune Response Against
Intestinal Antigen
Mice were orally immunized with OVA-microparticles 3
successive days with intragastric gavage. From 7 days
after the onset of immunization, mice were boosted twice
a week with the same antigen for 2 weeks. HET was
orally administered to them via the intragastric route
from 7 days before to 27 days after the onset of
immunization. The intestinal washes were collected
at day 27 from mice for measurement of titers of OVA-
specific IgA antibody. By oral immunization of
OVA-microparticle, OVA-specific IgA antibody was
successfully induced in intestine (Fig. 3A). When HET
was orally administered to the mice with the immuniza-
tion, OVA-specific IgA antibody titers in intestinal
washes were more significantly enhanced than that in
water-administered control (Fig. 3A). In order to know
whether HET enhances a basal level of secretory IgA
production in the mucosal site, total IgA titer in intestinal
washes were measured. No significant change in total IgA
antibody level was observed by administration of HET in
intestinal washes (Fig. 3B).
Enhancement of IgA Immune Response in the Distant
Mucosal Tissue Against Intestinal Antigen
To evaluate whether HET can stimulate IgA antibody
response in distant mucosal tissues, the OVA-specific
IgA antibody titers in nasal washes were measured. No
significant rise in OVA-specific IgA antibody titer in
nasal washes was observed by oral immunization of
OVA-microparticle alone (Fig. 3C). However, the IgA
antibody titers in nasal washes were markedly enhanced
by administration of HET, and the antibody titer was
significantly higher than that of nasal washes from
un-immunized mice (Fig. 3C). No significant change in
total IgA antibody level was observed by the admin-
istration of HET in nasal washes (Fig. 3D). These
results demonstrate the ability of orally administered
HET to act as a mucosal adjuvant for the induction of
specific IgA antibody responses in distant mucosal
tissues.
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To clarify the mechanisms of enhancement of mucosal
IgA antibody response by HET, we studied the effect of
HET on modulation of Th1-Th2 balance. When HET
(1000mgkg
1) was administered orally for 1 week, the
IFN-g secretions of lymphocytes from spleen, peripheral
blood and Peyer’s patches were significantly higher than
that of the cells from the control mice (Fig. 4A–C).
Whereas, the IL-4 secretions of lymphocytes from spleen,
peripheral blood and Peyer’s patches were not changed
by oral administration of HET (Fig. 4D–F). These results
suggest that HET may promote differentiation of the
lymphocytes toward the Th1 type cell.
Microarray Analysis of Gene Expression
in Peyer’s Patch Cells
Peyer’s patch is the important lymphoid tissues in the
intestine, and are known as the inductive sites for IgA
production (10). To study the mechanisms of enhance-
ment of mucosal IgA antibody response by HET, the
changes in gene expression of Peyer’s patch cells by
administration of HET were investigated using DNA
microarray. HET was administered for 1 week, and then
Peyer’s patch cells were isolated and gene expression was
analyzed by microarray. When expression of 500 genes in
Payer’s patch cells were analyzed, eight genes showed
significantly different expression in HET administered
mice compared with control (Table 1). Of the eight genes,
analysis focused on the up-regulation of L-selectin (also
known as CD62L) gene expression, because L-selectin
was widely considered most important for homing of
lymphocytes (11–13).
Increase of the L-selectin Positive Cells in B Lymphocytes
In order to confirm the up-regulation of L-selectin by
orally administered HET, the immunophenotypes of
Peyer’s patch cells and PBMC were investigated using
FCM. While the percentage of CD3
CD62L
 cells did
not change, the percentage of CD3
CD62L
+ cells was
increased significantly in Peyer’s patch cells from HET-
treated mice compared with vehicle control mice




 cells was increased significantly in both Peyer’s
patch cells and PBMC from HET-treated mice compared
with vehicle control mice (Table 2). It is widely known
that CD3 is one of surface marker of T lymphocytes.
Because both Peyer’s patch cells and PBMC were mainly
composed of T and B lymphocytes (data not shown), the
CD3
 cells were presumed to be B lymphocytes, though
Figure 4. Secretion of IFN-g and IL-4 by lymphocytes from the mice
orally administered HET. HET (1000mgkg
1) was orally administered
for 1 week, and then the lymphocytes were isolated from spleen,
peripheral blood and Payer’s patches, respectively. The lymphocytes
(2.510
6 cells ml
1) were cultured for 48h under the stimulation with
anti-CD3 antibody (1mgm l
1). After the culture of lymphocytes, the
culture supernatants were collected and the concentrations of IFN-g
and IL-4 were analyzed by ELISA. Data were expressed as meanSD
(n=10), and differences between groups were analyzed by Welch’s and
Student’s t-test.
Figure 3. Effect of oral administrations of HET on OVA-specific IgA
titer and total IgA antibody content in intestinal and nasal washes.
OVA was entrapped into microparticles and then administered orally
for immunization. Mice were immunized orally on days 0, 1, 2, 7, 10, 14
and 17 with 2mg of OVA antigen via the intragastric route. HET
(1000mgkg
1) were orally administered to the mice with intragastric
gavage from 7 days before to 27 days after the start of immunization.
The intestinal and nasal washes were collected at day 28, and then the
anti-OVA IgA antibody and total IgA content of the intestinal and
nasal washes were determined by ELISA. (A) Anti-OVA IgA titer of
intestinal wash. (B) Total IgA content of intestinal wash. (C) Anti-OVA
IgA titer of nasal wash. (D) Total IgA content of nasal wash. Note: in
our preliminary experiment, the administration of OVA free blank
microparticles did not induce IgA immune response in gastric mucosa
(data not shown). Data were expressed as meanSD (n=10), and
differences between groups were analyzed by ANOVA followed by post
hoc analysis using Scheffe’s test.
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 cells are needed. These
results suggest that orally administered HET up-regulates
the L-selectin positive cells in B lymphocytes.
Discussion
In order to analyze the effect of HET on IgA immune
response against intestinal antigen, HET was adminis-
tered to mice at a dose of 1000mgkg
1 per day, which is
equal to 20-fold for the clinical dose applied in human,
in this study. It is widely known that humans have
a low metabolic ability on drugs (14). Inversely,
drugs are metabolized in mice more quickly than
humans. Indeed, the hepatic clearance of drugs in
humans was approximately one-seventh of that of other
mammalians including mice (15). Furthermore, when
compared to renal clearance rate between humans and
mice, clearance in mice is about 10-fold greater than that
of humans (16). Therefore, we used relatively high
dosage.
OVA was chosen as an antigen because it has been
used widely in immunological experiments and is a well-
characterized antigen. However, oral administration of
OVA alone is difficult to induce IgA immune response in
gastric mucosa, because a small amount of the aqueous
OVA antigen can be easily degraded in the digestive
tract (17). Biodegradable microparticles have allowed
protection of orally administered antigens against enzy-
matic degradation, to increase antigen uptake into the
Peyer’s patches through M cells, to enhance mucosal
immune response and finally to induce a long and slow
antigen release (18–20). Therefore, to induce the OVA-
specific IgA antibody in mucosal site, OVA was
entrapped into microparticles and then administered
orally. By oral immunization of OVA-microparticle,
OVA-specific IgA antibody was successfully induced in
intestine and OVA-specific IgA titers in intestinal washes
were significantly enhanced by oral administration of
HET. These results suggest that orally administered HET
Table 2. Effect of orally administered HET on phenotype of lympho-
cytes from Peyer’s patches and peripheral blood.
Control HET P-value



























































 0.680.03 0.710.03 0.038
HET (1000mgkg
1) was orally administered for 1 week and then the
surface phenotype of cells was identified by using monoclonal
antibodies. Stained cells were analyzed by flow cytometry on EPICS
ELITE with logarithmic amplifier. Lymphoid cells were gated by the
forward and side scatters gating method for the analysis of the
lymphocytes population. Each value represents a meanSD (n=10).
The differences between groups were analyzed by Welch’s or Student’s
t-test.
Table 1. Effect of HET on gene expression in Peyer’s patch cells
Accession No Gene annotation Expression Fold change P-value
NM_009692 Apolipoprotein A-I (Apoa1) Up 1.7 4.010
4
Z16410 B-cell translocation gene 1 Up 2.3 2.110
5
NM_008008 Fibroblast growth factor 7 Down 2.7 2.310
2
X58712 Mitogen-activated protein kinase (p42) Up 2.0 5.410
4
NM_008562 Myeloid cell leukemia sequence 1 (Mcl1) Up 2.0 1.310
4
NM_011346 Selectin, lymphocyte (L-selectin, CD62L) Up 2.0 5.610
3
NM_011529 TRAF family member-associated NF-kappa B (Tank) Up 1.9 4.510
3
X99582 Leukocyte-derived seven transmembrane domain receptor Up 1.9 6.210
3
Oligonucleotides for microarray were synthesized in situ using photo deprotection chemistry with the Maskless Array Synthesizer system. HET was
administered for 1 week, and then Peyer’s patch cells were isolated and the gene expression was analyzed by the microarray. The data were extracted
from the raw images using NimbleScan software and then processed using NANDEMO Analysis software. Genes were regarded as changed if the
expression differed over 1.5-fold between the cells of HET and that of control.
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gens and food antigens in intestine. So far as we know,
this is the first description that oral administration of
HET-enhanced mucosal IgA response against intestinal
antigen.
The cytokine network plays an important role in
inflammatory and immune responses (21–23). IFN-g
and IL-4 are providing distinct help for either inflamma-
tory or humoral immune responses, and are expressed in
Th1 and Th2 cells, (24). Because the cytokine secretion
pattern of lymphocytes shift towards a Th1-like response
by oral administration of HET, the enhancement of
mucosal IgA antibody response by HET can not
be explained by the viewpoint of Th1-Th2 balance.
Most of the IgA producing B cells and plasma cells are
found in close proximity to the IEC, which lie on the
surface of the intestine. These IEC transport the secreted
IgA from the intestinal lamina propria across to the
intestinal lumen and therefore play an important role in
mucosal immune responses. However, several studies
have shown that IEC have the capacity to produce
several important immunoregulatory cytokines such as
IL-6, IL-7, IL-8, IL-10, tumor necrosis factor-a and
transforming growth factor-b reviewed in references
(25,26). HET might modulate cytokine secretion of
IEC, and the mucosal IgA antibody secretion might be
enhanced through action of these cytokines.
Polymeric immunoglobulin receptor (pIgR), also called
membrane secretory component (SC), of epithelial cells in
mucosa functions as a receptor for IgA (27), and it
facilitates the transport of IgA through epithelial cells
into surface of mucosa. Thus, pIgR is thought to be a
key factor in mucosal immunity. It has been reported
that IFN-g enhances expression of pIgR (28,29). In this
study, enhanced IFN-g secretion was observed by oral
administration of HET (Fig. 4A–C). Therefore, it is
inferred that HET up-regulates expression on pIgR of
epithelial cells in mucosal site via stimulation of IFN-g,
and the enhanced pIgR might partly contribute to the
enhanced IgA immune response. However, it is now not
known whether HET up-regulate pIgR. Further studies
are needed.
Mucosal immune systems in each local site such as
gastrointestinal, pulmonary and genitourinary tracts and
the exocrine glands connect each other through lympho-
cyte homing, and this intertissue communication is
named as common mucosal immune system (CMIS)
(30,31). Orally administered HET enhanced IgA immune
response in not only intestinal mucosa but also nasal
mucosa against orally administered OVA-microparticles.
The IgA immune response in nasal mucosa against
intestinal antigen may be explained by lymphocytes
homing via CMIS. However, detailed mechanism is not
known how HET enhanced IgA immune response in
nasal tissues distant from intestine. All high endothelial
venules of the nasal-associated lymphoid tissue, as well as
the draining head and neck lymph nodes referred to as
cranial-, oral-, and nasal-associated lymphoid tissue,
express peripheral lymph node vascular addressin
(PNAd), and most lymphocytes binding to these tissues
are mediated primarily through L-selectin–PNAd inter-
actions (32,33). Lymphocyte homing to the nasal cavity
and bronchopulmonary tissues in the humans and sheep
is mediated by L-selectin–PNAd interactions rather than
by mucosal addressin cell adhesin molecule-1
(MAdCAM-1)–a4b7 integrin interactions (34–36). The
results of DNA microarray and FCM analyses suggest
that orally administered HET up-regulates L-selectin
positive cells in B lymphocytes. Because L-selectin plays
an important role in the recruitment of B lymphocyte to
the non-intestinal mucosal effecter site (37,38), the
up-regulation of L-selectin positive B lymphocytes by
HET might partly contribute to the enhancement of IgA
immune response in nasal mucosa after oral immuniza-
tion with OVA-microparticles. In addition to L-selectin
gene, HET modulated the expression of seven genes
(Table 1). Presumably these gene products also play
important roles in the enhanced IgA immune response by
HET. In order to clarify the mechanism of enhanced IgA
immune response and role of these gene products, further
studies are required.
Our results revealed that HET enhances the mucosal
IgA immune response. HET consists of ten component
crude drugs, and is known to contain various com-
pounds, which may possess immunomodulatory and
immunosuppressive effects. Therefore, these may compli-
cate the interpretation of results. At this point, several
possibilities can be considered. Perhaps the HET extract
acts as a polyclonal B cell stimulator. Previously, we
reported on potent mitogenic polysaccharides from
Bupleuri Radix, Glycyrrhizae Radix, Astragali Radix,
Atractylodis lanceae Rhizoma, Ginseng Radix and
Angelicae Radix (39–41), which are component crude
drugs of HET. These polysaccharides may play a role in
the enhancement of IgA response via a polyclonal B cell
activation as active constituents in HET. The mechanism
of enhancement of IgA response by HET still remains
obscure. To elucidate the action mechanisms of HET and
active constituents in HET, further investigations are
necessary.
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